Chikusetsusaponin Iva

O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6C(O)=O)C5(C)C)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]7O)O)O[C@@H]7CO

[1]Cui J, et al. Insulinotropic effect of Chikusetsu saponin IVa in diabetic rats and pancreatic β-cells. J Ethnopharmacol. 2015 Apr 22;164:334-9.|[2]Li Y, et al. Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects. J Pharm Pharmacol. 2015 Jul;67 (7) :997-1007.|[3]Dahmer T, et al. Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (Maté) . J Med Food. 2012 Dec;15 (12) :1073-80.|[4]Xu G, et al. Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway. Z Naturforsch C J Biosci. 2020 Sep 28;76 (3-4) :103-110. |[5]Dai Q, et al. Chikusetsusaponin IVa Targets Nrf2 to Inhibit H9N2 Avian Influenza Virus Infection. Pharmacognosy Magazine, 2024: 09731296241277316.|[6]Wang H, et al. Inhibitory effects of Chikusetsusaponin IVa on lipopolysaccharide-induced pro-inflammatory responses in THP-1 cells. Int J Immunopathol Pharmacol. 2015 Sep;28 (3) :308-17.|[7]Gao K, et al. Chikusetsusaponin IVa targeted YAP as an inhibitor to attenuate liver fibrosis and hepatic stellate cell activation. Chin Med. 2025 Mar 17;20 (1) :36. |[8]Guo X, et al. Anti-inflammatory and osteoprotective effects of Chikusetsusaponin IVa on rheumatoid arthritis via the JAK/STAT signaling pathway. Phytomedicine. 2021 Dec;93:153801. |[9]Liu YW, et al. Identification of chikusetsusaponin IVa as a novel lysine-specific demethylase 1 inhibitor that ameliorates high fat diet-induced MASLD in mice. Acta Pharmacol Sin. 2025 Mar;46 (3) :632-652. |[10]Xu G, Lei H, Yuan Q, Chen H, Su J. Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway. Z Naturforsch C J Biosci. 2020 Sep 28;76 (3-4) :103-110.